Details of the Drug Combinations

General Information of This Drug (ID: DMM278X)

• Drug Name: Adefovir (DMM278X)
• Synonyms: ((2-(6-Amino-9H-purin-9-yl)ethoxy)methyl)phosphonic acid; 2-(6-aminopurin-9-yl)ethoxymethylphosphonic acid; 9-(2-(Phosphonomethoxy)ethyl)adenine; 9-(2-Phosphonylmethoxyethyl)adenine; ADEFOVIR; GS 0393; GS 393; GS-0393; N-(2-Phophonomethoxyethyl-2,6-diaminopurine); N-(2-Phosphonylmethoxyethyl)adenine; PMEA; {[2-(6-Amino-9h-Purin-9-Yl)ethoxy]methyl}phosphonic Acid
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

6 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
AKB-6548 + Adefovir	DCVZK1N	AKB-6548	Drug Interaction Potentiation	[1]
Clevudine + Adefovir	DCA9F13	Clevudine	Chronic Hepatitis B	[2]
Entecavir + Adefovir	DC5MTN9	Entecavir	Hepatitis B, Chronic	[3]
Lamivudine + Adefovir	DCA60F9	Lamivudine	Chronic Hepatitis B	[2]
Lamivudine + Adefovir	DCJSNX7	Lamivudine	Hepatitis B, Chronic	[3]
Entecavir + Adefovir	DCE88RB	Entecavir	Hepatitis B, Chronic	[4]

References

• [1] ClinicalTrials.gov (NCT03801759) Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide
• [2] ClinicalTrials.gov (NCT00798460) Efficacy of Clevudine Plus Lamivudine for Lamivudine-resistant Chronic Hepatitis B Patients
• [3] ClinicalTrials.gov (NCT00410202) Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus
• [4] ClinicalTrials.gov (NCT02482272) Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B